Fu et al. (2021) found a PD-L1 positivity rate of 50% (7/14) in tumour cells of a MYD88L265P group compared to 18.4% in a non-MYD88L265P group of patients with DLBCL (9/49), which implies the possibility that combination therapy can be used. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.